headache
Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial
July 11, 2019Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma
Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …
Eli Lilly’s Emgality shows positive Phase 3 results in treatment of migraine
May 8, 2019Research and Development Eli Lilly, Emgality, cluster headache, headache, migraine, pharma
Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the …
Teva terminates Ajovy at Phase 3 in episodic cluster headache
April 24, 2019Research and Development Teva, ajovy, headache, pharma
Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy …
Teva axes Phase 3 trial into chronic cluster headache
June 18, 2018Research and Development, Sales and Marketing Teva, fremanezumab, headache, pharma
With the advent of another week, there’s another trial discontinuation in the industry as Teva announces its decision to terminate …
Lilly’s galcanezumab soars in episodic cluster headache, but fails in chronic form
May 16, 2018Research and Development Eli Lilly, galcanezumab, headache, migraine, pharma
Eli Lilly has released new Phase 3 results for its CGRP inhibitor galcanezumab in the treatment of episodic cluster headache, …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
